Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Endometrial cancer biological marker

An endometrial cancer, substance technology, applied in the field of treatment, prediction of prognosis, cancer diagnosis, which can solve the problems of elevated levels, lack of tissue sensitivity and specificity, etc.

Active Publication Date: 2016-08-31
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, CA-125 lacks tissue sensitivity and specificity, and elevated levels of CA-125 can be detected in ovarian epithelial tumors, endometrial cancer, endometriosis, and digestive system tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Endometrial cancer biological marker
  • Endometrial cancer biological marker
  • Endometrial cancer biological marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0069] Example 1 Gene Chip Screening for Differentially Expressed Genes

[0070] 1. Sample collection:

[0071] Endometrial cancer tissue samples: Patients with endometrial cancer were collected, all of whom underwent surgical treatment, and 10 surgical paraffin specimens were collected. All patients were diagnosed with endometrial cancer by pathological examination. Other enrollment conditions are: all patients have not received any treatment before admission; no other malignant tumors; no other hormone-related diseases; complete clinical data.

[0072] 10 cases of endometrial cancer patients, the average age of onset was 58 years old. The main clinical manifestations of patients are irregular vaginal bleeding, lower abdominal pain, menstrual disorders, vaginal discharge, etc. There are also some patients who have no obvious symptoms and are found in physical examination. The endometrial cancer specimens were sectioned by HE staining, and the histomorphological diagnosis w...

Embodiment 2

[0084] Example 2 Large sample verification screened out differentially expressed genes

[0085] Considering the gene that has not been studied in the prior art on the correlation between this gene and endometrial cancer as a candidate gene, and considering the results of gene sequencing, select the SPARCL1 gene (its expression is down-regulated in endometrial cancer tissue) for verification .

[0086] 1. Sample collection

[0087] According to the method of Example 1, 50 cases of endometrial cancer tissues and 60 cases of normal endometrial tissues were collected.

[0088] 2. Validation at the mRNA level

[0089] 2.1 Extract tissue RNA

[0090] Step is with embodiment 1.

[0091] 2.2 Reverse transcription

[0092] Using a reverse transcription kit, 1 μg of total RNA was reverse-transcribed with reverse transcription buffer to synthesize cDNA. Use 25μl reaction system, take 1μg total RNA for each sample as template RNA, and add the following components in PCR tubes: DEPC ...

Embodiment 3

[0116] Example 3 Overexpression of SPARCL1 gene

[0117] 1. Plasmid construction

[0118] Amplification primers are designed according to the coding sequence of the SPARCL1 gene, and the design of primers is well known to those skilled in the art. Amplify the coding sequence of the full-length SPARCL1 gene from the cDNA library of adult fetal brain (clontech company, article number: 638831), insert the above cDNA sequence into the eukaryotic cell expression vector pcDNA3.1, and connect the obtained recombinant vector pcDNA3.1 -SPARCL1 was used in subsequent experiments.

[0119] 2. Culture and transfection of endometrial cancer cells

[0120] 2.1 Cell culture

[0121] The Ishikawa3-H-12 cell line was cultured in RPMI 1640 medium (containing 10% fetal bovine serum, 100 U / ml penicillin, 100 g / ml streptomycin) in 50 ml culture flasks, at 37 °C, 5% CO 2Continuous cultivation in a humidified incubator.

[0122] 2.2 Cell transfection

[0123] 1. The day before transfection, 0....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of SPARCL1 to a diagnosis and treatment marker of endometrial cancer. The SPARCL1 can be used for developing a product for diagnosing the endometrial cancer and developing a medicine for treating the endometrial cancer. A research result of the invention provides a theoretical foundation for formulating personalized treatment programs by clinical doctors and provides a new medicine target spot for developing endometrial cancer medicines.

Description

technical field [0001] The present invention relates to the fields of cancer diagnosis, treatment, and prognosis prediction. More specifically, the present invention relates to a cancer diagnosis and prognosis prediction method by means of detecting SPARCL1 abnormality; and a cancer therapeutic agent for activating SPARCL1 gene or protein. Background technique [0002] Endometrial cancer (endometrial carcinoma or carcinoma of endometrium, EC) is a group of epithelial malignant tumors that occur in the endometrium, and adenocarcinoma derived from endometrial glands is the most common, and it is the three major malignant tumors of the female reproductive tract. One of them, it accounts for 7% of malignant tumors in women, and its incidence varies in different regions of the world. It is the most common gynecological malignant tumor in western industrialized countries, with the highest incidence in North America and Northern Europe, Asia, Japan, India, Central and South America,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68G01N33/574A61K45/00A61P35/00
CPCA61K45/00C12Q1/6886C12Q2600/118C12Q2600/158G01N33/57442G01N33/57484
Inventor 杨承刚任静
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com